Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bafna Pharmaceuticals's Enterprise Value is ₹5,033 Mil.
Bafna Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹146 Mil. Therefore, Bafna Pharmaceuticals's EV-to-EBIT ratio for today is 34.40.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Bafna Pharmaceuticals's Enterprise Value is ₹5,033 Mil.
Bafna Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹207 Mil. Therefore, Bafna Pharmaceuticals's EV-to-EBITDA ratio for today is 24.31.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Bafna Pharmaceuticals (NSE:BAFNAPH) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Bafna Pharmaceuticals's current Enterprise Value is ₹5,033 Mil.
Bafna Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹146 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Bafna Pharmaceuticals's EV-to-EBITDA for today is:
Bafna Pharmaceuticals's current Enterprise Value is ₹5,033 Mil.
Bafna Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹207 Mil.
Bafna Pharmaceuticals's current Enterprise Value is ₹5,033 Mil.
Bafna Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,506 Mil.
Bafna Pharmaceuticals's current Enterprise Value is ₹5,033 Mil.
Bafna Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
Bafna Pharmaceuticals's current Enterprise Value is ₹5,033 Mil.
Bafna Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bafna Pharmaceuticals Enterprise Value Related Terms
Bafna Pharmaceuticals Enterprise Value Historical Data
* Premium members only.
The historical data trend for Bafna Pharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's Enterprise Value falls into.
Bafna Pharmaceuticals Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Bafna Pharmaceuticals's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Enterprise Value of ₹5,033 Mil as of Jun. 27, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Bafna Pharmaceuticals and its competitors.
Is Bafna Pharmaceuticals' Enterprise Value too high?
Bafna Pharmaceuticals' current Enterprise Value is ₹5,033 Mil. Overall, Bafna Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Enterprise Value compare to ZTS?
Bafna Pharmaceuticals' Enterprise Value of ₹5,033 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Bafna Pharmaceuticals and its competitors. Bafna Pharmaceuticals's current Enterprise Value is ₹5,033 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹90.56, compared to a current price of ₹194.68 — trading 115% above its estimated fair value. The current Enterprise Value is ₹5,033 Mil. Bafna Pharmaceuticals' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Enterprise Value is ₹5,033 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹194.68 is trading 115% above its estimated GF Value™ of ₹90.56.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
Enterprise Value: ₹5,033 Mil
GF Value™: ₹90.56 vs. price of ₹194.68 (115% above fair value)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
59GF Score
Get the complete analysis for NSE:BAFNAPH
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
